Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06934200
PHASE2

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.

Key Details

Gender

All

Age Range

1 Year - 55 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2025-05-19

Completion Date

2027-10-15

Last Updated

2025-06-05

Healthy Volunteers

No

Interventions

DRUG

Omalizumab

omalizumab injections

Locations (1)

Johns Hopkins

Baltimore, Maryland, United States